Functional analysis of the p57 KIP2 gene mutation in Beckwith-Wiedemann syndrome
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
p57 KIP2 is a potent tight-binding inhibitor of several G1 cyclin/cyclin-dependent kinase (Cdk) complexes, and is a negative regulator of cell proliferation. The gene encoding p57 KIP2 is located at 11p15.5, a region implicated in both sporadic cancers and Beckwith-Wiedemann syndrome (BWS). Previously we demonstrated that p57 KIP2 is imprinted and only the maternal allele is expressed in both mice and humans. We also showed mutations found in p57 KIP2 in patients with BWS that were transmitted from the patients’ carrier mothers, indicating that the expressed maternal allele was mutant and that the repressed paternal allele was normal. In the study reported here, we performed functional analysis of the two mutated p57 KIP2 genes. We showed that the nonsense mutation found in the Cdk inhibitory domain in a BWS patient rendered the protein inactive with consequent complete loss of its role as a cell cycle inhibitor and of its nuclear localization. We also showed that the mutation in the QT domain, although completely retaining its cell cycle regulatory activity, lacked nuclear localization and was thus prevented from performing its role as an active cell cycle inhibitor. Consequently, no active p57 KIP2 would have existed, which might have caused the disorders in BWS patients.
- Functional analysis of the p57 KIP2 gene mutation in Beckwith-Wiedemann syndrome
Volume 104, Issue 3 , pp 205-210
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Author Affiliations
- A1. Department of Bioscience, National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan, JP
- A2. Department of Biochemistry, Saga Medical School, 5-1-1 Nabeshima, Saga 849-8501, Japan e-mail: email@example.com, Tel.: +81-952-34-2260, Fax: +81-952-34-2067, JP